CIK 1583107

Theravance Biopharma, Inc.

EDGAR filings

Customers

1 disclosed

Suppliers

None disclosed

Largest customer

100%

VTRS · FY to 2025-12-31

Named-customer revenue

$107.5M

1 customer · FY to 2025-12-31

Latest period

Dec 31, 2025

10-K filed 2026-03-23

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Customers 1

Companies Theravance Biopharma, Inc. discloses as major customers, as a share of Theravance Biopharma, Inc. revenue. 1 active, 0 lapsed.

Company	% of Theravance Biopharma, Inc. revenue	Est. revenue	Period	Trend	Status	Source
VTRS Viatris Inc	100%	$107.5M	FY 2025-12-31	±0.0pp	Active	10-K 2026-03-23
YUPELRI net sales (100% recorded by Viatris) $ 266,600 $ 238,626 $ 27,974 12 % 10-K filed 2026-03-23 Period FY 2025-01-01 to 2025-12-31 (100%), FY 2024-01-01 to 2024-12-31 (100%)Accession 0001104659-26-033077

Alerts are coming

Get an email when Theravance Biopharma, Inc.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.